6 búsqueda de la palabra clave 'lupus nephritis'

Development and Internal Validation of a Prediction Model to Estimate the Probability of Needing Aggressive Immunosuppressive Therapy With Cytostatics in de Novo Lupus Nephritis Patients / Mauricio Restrepo Escobar ; Paula Andrea Granda Carvajal ; Fabián Alberto Jaimes Barragán  

Público ISBD Título : Development and Internal Validation of a Prediction Model to Estimate the Probability of Needing Aggressive Immunosuppressive Therapy With Cytostatics in de Novo Lupus Nephritis Patients Otros títulos : Desarrollo y validación interna de un modelo de predicción para estimar la probabilidad de requerir inmunosupresión intensiva con citostáticos en pacientes con nefritis lúpica de novo Tipo de documento : documento electrónico Autores : Mauricio Restrepo Escobar, ; Paula Andrea Granda Carvajal, ; Fabián Alberto Jaimes Barragán, Fecha de publicación : 2019 Títulos uniformes : Reumatología Clínica Idioma : Inglés (eng) Palabras clave : Systemic lupus erythematosus  lupus nephritis  immunosuppression  multivariate analysis  decision support techniques  logistic models Resumen : Objective: To develop a multivariable clinical prediction model for the requirement of aggressive immunosuppression with cytostatics, based on simple clinical record data and lab tests. The model is defined in accordance with the result of the kidney biopsies. Methods: Retrospective study conducted with data from patients 16 years and older, with SLE and nephritis with less than 6 months of evolution. An initial bivariate analysis was conducted to select the variables to be included in a multiple logistic regression model. Goodness of fit was evaluated using a Hosmer–Lemeshow test (H–L) and the discrimination capacity of the model by means of the area under the ROC (AUC) curve. Results: Data from 242 patients was gathered; of these, 18.2% (n = 44) did not need an addition of cytostatics according to the findings of their kidney biopsies. The variables included in the final model were 24-h proteinuria, diastolic blood pressure, creatinine, C3 complement and the interaction of hematuria with leukocyturia in urinary sediment. The model showed excellent discrimination (AUC = 0.929; 95% CI = 0.894–0.963) and adequate calibration (H–L, P = .959). Conclusion: In recent-onset LN patients, the decision to use or not to use intensive immunosuppressive therapy could be performed based on our prediction model as an alternative to kidney biopsies. Mención de responsabilidad : Mauricio Restrepo-Escobar, Paula Andrea Granda-Carvajal, Fabián Jaimes Referencia : Reumatol Clin. 2019 Jan - Feb;15(1):27-33. DOI (Digital Object Identifier) : 10.1016/j.reuma.2017.05.010 PMID : 28732643 En línea : https://www.reumatologiaclinica.org/en-linkresolver-development-internal-validat [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Development and Internal Validation of a Prediction Model to Estimate the Probability of Needing Aggressive Immunosuppressive Therapy With Cytostatics in de Novo Lupus Nephritis Patients = Desarrollo y validación interna de un modelo de predicción para estimar la probabilidad de requerir inmunosupresión intensiva con citostáticos en pacientes con nefritis lúpica de novo [documento electrónico] / Mauricio Restrepo Escobar, ; Paula Andrea Granda Carvajal, ; Fabián Alberto Jaimes Barragán,  . - 2019. Obra : Reumatología Clínica Idioma : Inglés (eng) Palabras clave : Systemic lupus erythematosus  lupus nephritis  immunosuppression  multivariate analysis  decision support techniques  logistic models Resumen : Objective: To develop a multivariable clinical prediction model for the requirement of aggressive immunosuppression with cytostatics, based on simple clinical record data and lab tests. The model is defined in accordance with the result of the kidney biopsies. Methods: Retrospective study conducted with data from patients 16 years and older, with SLE and nephritis with less than 6 months of evolution. An initial bivariate analysis was conducted to select the variables to be included in a multiple logistic regression model. Goodness of fit was evaluated using a Hosmer–Lemeshow test (H–L) and the discrimination capacity of the model by means of the area under the ROC (AUC) curve. Results: Data from 242 patients was gathered; of these, 18.2% (n = 44) did not need an addition of cytostatics according to the findings of their kidney biopsies. The variables included in the final model were 24-h proteinuria, diastolic blood pressure, creatinine, C3 complement and the interaction of hematuria with leukocyturia in urinary sediment. The model showed excellent discrimination (AUC = 0.929; 95% CI = 0.894–0.963) and adequate calibration (H–L, P = .959). Conclusion: In recent-onset LN patients, the decision to use or not to use intensive immunosuppressive therapy could be performed based on our prediction model as an alternative to kidney biopsies. Mención de responsabilidad : Mauricio Restrepo-Escobar, Paula Andrea Granda-Carvajal, Fabián Jaimes Referencia : Reumatol Clin. 2019 Jan - Feb;15(1):27-33. DOI (Digital Object Identifier) : 10.1016/j.reuma.2017.05.010 PMID : 28732643 En línea : https://www.reumatologiaclinica.org/en-linkresolver-development-internal-validat [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000652	AC-2017-041	Archivo digital	Producción Científica	Artículos científicos	Disponible

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) / Ruth María Eraso Garnica  

Público ISBD Título : First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) Tipo de documento : documento electrónico Autores : Ruth María Eraso Garnica, Fecha de publicación : 2018 Títulos uniformes : Annals of the Rheumatic Diseases Idioma : Inglés (eng) Palabras clave : Lupus nephritis  systemic lupus erythematosus  treatment Resumen : Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings. Mención de responsabilidad : Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Margarita Duarte, Leonor A Barile-Fabris, Mercedes A García, Mary-Carmen Amigo, Graciela Espada, Luis J Catoggio, Emilia Inoue Sato, Roger A Levy, Eduardo M Acevedo Vásquez, Rosa Chacón-Díaz, Claudio M Galarza-Maldonado, Antonio J Iglesias Gamarra, José Fernando Molina, Oscar Neira, Clóvis A Silva, Andrea Vargas Peña, José A Gómez-Puerta, Marina Scolnik, Guillermo J Pons-Estel, Michelle R Ugolini-Lopes, Verónica Savio, Cristina Drenkard, Alejandro J Alvarellos, Manuel F Ugarte-Gil, Alejandra Babini, André Cavalcanti, Fernanda Athayde Cardoso Linhares, Maria Jezabel Haye Salinas, Yurilis J Fuentes-Silva, Ana Carolina Montandon de Oliveira E Silva, Ruth M Eraso Garnica, Sebastián Herrera Uribe, Diana Gómez-Martín, Ricardo Robaina Sevrini, Rosana M Quintana, Sergio Gordon, Hilda Fragoso-Loyo, Violeta Rosario, Verónica Saurit, Simone App Referencia : Ann Rheum Dis. 2018 Nov;77(11):1549-1557. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2018-213512 PMID : 30045853 En línea : https://ard.bmj.com/content/77/11/1549 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) [documento electrónico] / Ruth María Eraso Garnica,  . - 2018. Obra : Annals of the Rheumatic Diseases Idioma : Inglés (eng) Palabras clave : Lupus nephritis  systemic lupus erythematosus  treatment Resumen : Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings. Mención de responsabilidad : Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Margarita Duarte, Leonor A Barile-Fabris, Mercedes A García, Mary-Carmen Amigo, Graciela Espada, Luis J Catoggio, Emilia Inoue Sato, Roger A Levy, Eduardo M Acevedo Vásquez, Rosa Chacón-Díaz, Claudio M Galarza-Maldonado, Antonio J Iglesias Gamarra, José Fernando Molina, Oscar Neira, Clóvis A Silva, Andrea Vargas Peña, José A Gómez-Puerta, Marina Scolnik, Guillermo J Pons-Estel, Michelle R Ugolini-Lopes, Verónica Savio, Cristina Drenkard, Alejandro J Alvarellos, Manuel F Ugarte-Gil, Alejandra Babini, André Cavalcanti, Fernanda Athayde Cardoso Linhares, Maria Jezabel Haye Salinas, Yurilis J Fuentes-Silva, Ana Carolina Montandon de Oliveira E Silva, Ruth M Eraso Garnica, Sebastián Herrera Uribe, Diana Gómez-Martín, Ricardo Robaina Sevrini, Rosana M Quintana, Sergio Gordon, Hilda Fragoso-Loyo, Violeta Rosario, Verónica Saurit, Simone App Referencia : Ann Rheum Dis. 2018 Nov;77(11):1549-1557. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2018-213512 PMID : 30045853 En línea : https://ard.bmj.com/content/77/11/1549 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000792	AC-2018-079	Archivo digital	Producción Científica	Artículos científicos	Disponible

Clinicopathological relationship in Colombian patients with lupus nephritis / Luis Fernando Pinto Peñaranda  

Público ISBD Título : Clinicopathological relationship in Colombian patients with lupus nephritis Otros títulos : Relación clí­nicopatológica en pacientes colombianos con nefritis lúpica Tipo de documento : documento electrónico Autores : Luis Fernando Pinto Peñaranda, Fecha de publicación : 2017 Títulos uniformes : Revista Colombiana de Reumatología Idioma : Inglés (eng) Palabras clave : Lupus nephritis  Systemic lupus erythematosus  Biopsy  Proteinuria  Creatinine  Hispanic Americans Resumen : Background: There are several clinical and laboratory features for lupus nephritis diagnosis; however, renal biopsy remains as the gold standard. Different series have tried to establish the relationship between these findings, with conflicting results. Objective: To describe the correlation between clinical and laboratory variables with histological biopsy-proven lupus nephritis. Methods: An analytical cross-sectional study was conducted, between January, 2004 and December, 2012. Qualitative variables were described using absolute and relative frequencies, while quantitative variables were assessed by medians with interquartile range. The relationship with clinical findings was explored using chi-square maximum likelihood test, adjusted standardized residuals, hierarchical Kruskal–Wallis test, homogeneity of variance in data, post hoc Dunn's test, Spearman's correlation coefficient, and Mann–Whitney test. Results: 132 patients were included. Proliferative lupus nephritis was the most frequent (74%). The most common clinical condition was nephritic syndrome (46%); proteinuria was observed in 80%. No relationship was found between clinical syndromes and histological types; only statistically significant differences were observed between proliferative and non-proliferative forms regarding hematuria (72.1 vs. 46.7%; p = 0.012), C3 hypocomplementemia (70.9 vs. 43.3%; p = 0.007), 24-h proteinuria (2560 vs 741 mg; p = 0.001), and serum creatinine (1 vs. 0.77 mg/dL; p = 0.006). We found positive correlations between activity index and serum creatinine values, 24-h proteinuria, C3 hypocomplementemia, along with positive anti-DNA antibodies. Conclusion: There is a clinicopathological relationship within proliferative types and certain laboratory features (hematuria, elevated 24-h protein excretion, serum creatinine level, and C3 hypocomplementemia) in a mestizo population with lupus nephritis; nonetheless, no association was found with any other variables. Mención de responsabilidad : Carlos Jaime Velásquez-Franco, Yerlin Andrés Colina Vargas, Sara Correa Pérez, Felipe Osorio Ospina, Mariana Tamayo Correa, Juliana Madrid Vargas, Aura Ligia Zapata-Castellanos, Libia María Rodríguez Padilla, Luis Fernando Pinto Peñaranda y Miguel Antonio Mesa Navas DOI (Digital Object Identifier) : 10.1016/j.rcreu.2017.10.001 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0121812317301068 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Clinicopathological relationship in Colombian patients with lupus nephritis = Relación clí­nicopatológica en pacientes colombianos con nefritis lúpica [documento electrónico] / Luis Fernando Pinto Peñaranda,  . - 2017. Obra : Revista Colombiana de Reumatología Idioma : Inglés (eng) Palabras clave : Lupus nephritis  Systemic lupus erythematosus  Biopsy  Proteinuria  Creatinine  Hispanic Americans Resumen : Background: There are several clinical and laboratory features for lupus nephritis diagnosis; however, renal biopsy remains as the gold standard. Different series have tried to establish the relationship between these findings, with conflicting results. Objective: To describe the correlation between clinical and laboratory variables with histological biopsy-proven lupus nephritis. Methods: An analytical cross-sectional study was conducted, between January, 2004 and December, 2012. Qualitative variables were described using absolute and relative frequencies, while quantitative variables were assessed by medians with interquartile range. The relationship with clinical findings was explored using chi-square maximum likelihood test, adjusted standardized residuals, hierarchical Kruskal–Wallis test, homogeneity of variance in data, post hoc Dunn's test, Spearman's correlation coefficient, and Mann–Whitney test. Results: 132 patients were included. Proliferative lupus nephritis was the most frequent (74%). The most common clinical condition was nephritic syndrome (46%); proteinuria was observed in 80%. No relationship was found between clinical syndromes and histological types; only statistically significant differences were observed between proliferative and non-proliferative forms regarding hematuria (72.1 vs. 46.7%; p = 0.012), C3 hypocomplementemia (70.9 vs. 43.3%; p = 0.007), 24-h proteinuria (2560 vs 741 mg; p = 0.001), and serum creatinine (1 vs. 0.77 mg/dL; p = 0.006). We found positive correlations between activity index and serum creatinine values, 24-h proteinuria, C3 hypocomplementemia, along with positive anti-DNA antibodies. Conclusion: There is a clinicopathological relationship within proliferative types and certain laboratory features (hematuria, elevated 24-h protein excretion, serum creatinine level, and C3 hypocomplementemia) in a mestizo population with lupus nephritis; nonetheless, no association was found with any other variables. Mención de responsabilidad : Carlos Jaime Velásquez-Franco, Yerlin Andrés Colina Vargas, Sara Correa Pérez, Felipe Osorio Ospina, Mariana Tamayo Correa, Juliana Madrid Vargas, Aura Ligia Zapata-Castellanos, Libia María Rodríguez Padilla, Luis Fernando Pinto Peñaranda y Miguel Antonio Mesa Navas DOI (Digital Object Identifier) : 10.1016/j.rcreu.2017.10.001 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0121812317301068 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001158	AC-2017-112	Archivo digital	Producción Científica	Artículos científicos	Disponible

Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy / John Fredy Nieto Ríos ; Catalina Ocampo Kohn ; Arbey Aristizabal Álzate ; Lina Maria Serna Higuita ; Ricardo César Restrepo Correa ; Natalia Cardona Díaz    

Público ISBD Título : Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy Otros títulos : Resultados clínicos de trasplantes de riñón en pacientes con enfermedad renal en etapa terminal secundaria anefritis lupus, enfermedad poliquística renal y nefropatía diabética Tipo de documento : documento electrónico Autores : John Fredy Nieto Ríos, ; Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; Lina Maria Serna Higuita, ; Ricardo César Restrepo Correa, ; Natalia Cardona Díaz, Fecha de publicación : 2016 Títulos uniformes : Colombia Médica Idioma : Inglés (eng) Palabras clave : Kidney transplant  Lupus nephritis  Diabetic nephropathy  Polycystic kidney disease Resumen : Background: Patients with lupus nephritis could progress to end-stage renal disease (10-22%); hence, kidney transplants should be considered as the treatment of choice for these patients. Objective: To evaluate the clinical outcomes after kidney transplants in patients with chronic kidney diseases secondary to lupus nephritis, polycystic kidney disease and diabetes nephropathy at Pablo Tobon Uribe Hospital. Methods: A descriptive and retrospective study performed at one kidney transplant center between 2005 and 2013. Results: A total of 136 patients, 27 with lupus nephritis (19.9%), 31 with polycystic kidney disease (22.8%) and 78 with diabetes nephropathy (57.4%), were included in the study. The graft survivals after one, three and five years were 96.3%, 82.5% and 82.5% for lupus nephritis; 90%, 86% and 76.5% for polycystic kidney disease and 91.7%, 80.3% and 67.9% for diabetes nephropathy, respectively, with no significant differences (p= 0.488); the rate of lupus nephritis recurrence was 0.94%/person-year. The etiology of lupus vs diabetes vs polycystic disease was not a risk factor for a decreased time of graft survival (Hazard ratio: 1.43; 95% CI: 0.52-3.93). Conclusion: Kidney transplant patients with end stage renal disease secondary to lupus nephritis has similar graft and patient survival success rates to patients with other kidney diseases. The complication rate and risk of recurrence for lupus nephritis are low. Kidney transplants should be considered as the treatment of choice for patients with end stage renal disease secondary to lupus nephritis. Mención de responsabilidad : John Fredy Nieto-Ríos, Lina María Serna-Higuita, Sheila Alexandra Builes-Rodriguez, Ricardo Cesar Restrepo-Correa, Arbey Aristizabal-Alzate, Catalina Ocampo-Kohn, Angélica Serna-Campuzano, Natalia Cardona-Díaz, Nelson Darío Giraldo-Ramirez, Gustavo Adolfo Zuluaga-Valencia Referencia : Colomb Med (Cali). 2016 Mar 30;47(1):51-8. DOI (Digital Object Identifier) : 10.25100/cm.v47i1.2085 PMID : 27226665 Derechos de uso : CC BY En línea : https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/2085 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy = Resultados clínicos de trasplantes de riñón en pacientes con enfermedad renal en etapa terminal secundaria anefritis lupus, enfermedad poliquística renal y nefropatía diabética [documento electrónico] / John Fredy Nieto Ríos, ; Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; Lina Maria Serna Higuita, ; Ricardo César Restrepo Correa, ; Natalia Cardona Díaz,  . - 2016. Obra : Colombia Médica Idioma : Inglés (eng) Palabras clave : Kidney transplant  Lupus nephritis  Diabetic nephropathy  Polycystic kidney disease Resumen : Background: Patients with lupus nephritis could progress to end-stage renal disease (10-22%); hence, kidney transplants should be considered as the treatment of choice for these patients. Objective: To evaluate the clinical outcomes after kidney transplants in patients with chronic kidney diseases secondary to lupus nephritis, polycystic kidney disease and diabetes nephropathy at Pablo Tobon Uribe Hospital. Methods: A descriptive and retrospective study performed at one kidney transplant center between 2005 and 2013. Results: A total of 136 patients, 27 with lupus nephritis (19.9%), 31 with polycystic kidney disease (22.8%) and 78 with diabetes nephropathy (57.4%), were included in the study. The graft survivals after one, three and five years were 96.3%, 82.5% and 82.5% for lupus nephritis; 90%, 86% and 76.5% for polycystic kidney disease and 91.7%, 80.3% and 67.9% for diabetes nephropathy, respectively, with no significant differences (p= 0.488); the rate of lupus nephritis recurrence was 0.94%/person-year. The etiology of lupus vs diabetes vs polycystic disease was not a risk factor for a decreased time of graft survival (Hazard ratio: 1.43; 95% CI: 0.52-3.93). Conclusion: Kidney transplant patients with end stage renal disease secondary to lupus nephritis has similar graft and patient survival success rates to patients with other kidney diseases. The complication rate and risk of recurrence for lupus nephritis are low. Kidney transplants should be considered as the treatment of choice for patients with end stage renal disease secondary to lupus nephritis. Mención de responsabilidad : John Fredy Nieto-Ríos, Lina María Serna-Higuita, Sheila Alexandra Builes-Rodriguez, Ricardo Cesar Restrepo-Correa, Arbey Aristizabal-Alzate, Catalina Ocampo-Kohn, Angélica Serna-Campuzano, Natalia Cardona-Díaz, Nelson Darío Giraldo-Ramirez, Gustavo Adolfo Zuluaga-Valencia Referencia : Colomb Med (Cali). 2016 Mar 30;47(1):51-8. DOI (Digital Object Identifier) : 10.25100/cm.v47i1.2085 PMID : 27226665 Derechos de uso : CC BY En línea : https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/2085 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000571	AC-2016-046	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2016-046.pdf Adobe Acrobat PDF

Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis / Luis Fernando Pinto Peñaranda ; Javier Darío Márquez Hernández ; Carolina Muñoz Grajales ; Carlos Jaime Velásquez Franco  

Público ISBD Título : Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis Tipo de documento : documento electrónico Autores : Luis Fernando Pinto Peñaranda, ; Javier Darío Márquez Hernández, ; Carolina Muñoz Grajales, ; Carlos Jaime Velásquez Franco, Fecha de publicación : 2015 Títulos uniformes : Clinical Rheumatology Idioma : Inglés (eng) Palabras clave : Latin American mestizo  lupus nephritis  nephrotic syndrome  proteinuria  remission induction Resumen : The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12 months in a group of patients with proliferative lupus nephritis from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with systemic lupus erythematosus as defined by the American College of Rheumatology with biopsy-proven nephritis. We assessed 149 patients, with 84 % female. Age at diagnosis of systemic lupus erythematosus is 24.7 years (16–31). The time between diagnosis of lupus erythematosus and proliferative nephritis is 2 months (0–35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8 %), III (13.4 %), V + III (3.3 %), and V + IV (3.3 %). Activity index is 6.18 ± 4.55 and chronicity index is 1 (0–3). The result of 24-h proteinuria is 2000 mg (667–4770) and baseline creatinine is 0.9 mg/dL (0.7–1.3). Induction therapy includes corticosteroids (100 %), cyclophosphamide (74.1 %), and mycophenolate mofetil (25.9 %). At 12 months, 40.7 % of individuals failed to attain partial or complete remission. Elevated creatinine (p = 0.0001) and 24-h proteinuria greater than 1500 mg (p = 0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline creatinine elevation (OR 3.62, 95 % CI, 1.59–8.23; p = 0.002) and 24-h proteinuria greater than 1500 mg (OR 3.62, 95 % CI, 1.29–10.13; p = 0.014) were independent predictors of failure to achieve partial or complete remission. At 12 months, 40.7 % of patients did not attain partial or complete remission. Baseline elevated creatinine and 24-h proteinuria over 1500 mg were predictors for poor response. Mención de responsabilidad : Luis Fernando Pinto-Peñaranda, Vladimir Duque-Caballero, Javier Darío Márquez-Hernández, Carolina Muñoz-Grajales, Carlos Jaime Velásquez-Franco Referencia : Clin Rheumatol. 2015 May;34(5):897-903. DOI (Digital Object Identifier) : 10.1007/s10067-015-2864-7 PMID : 25592376 En línea : https://link.springer.com/article/10.1007%2Fs10067-015-2864-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis [documento electrónico] / Luis Fernando Pinto Peñaranda, ; Javier Darío Márquez Hernández, ; Carolina Muñoz Grajales, ; Carlos Jaime Velásquez Franco,  . - 2015. Obra : Clinical Rheumatology Idioma : Inglés (eng) Palabras clave : Latin American mestizo  lupus nephritis  nephrotic syndrome  proteinuria  remission induction Resumen : The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12 months in a group of patients with proliferative lupus nephritis from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with systemic lupus erythematosus as defined by the American College of Rheumatology with biopsy-proven nephritis. We assessed 149 patients, with 84 % female. Age at diagnosis of systemic lupus erythematosus is 24.7 years (16–31). The time between diagnosis of lupus erythematosus and proliferative nephritis is 2 months (0–35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8 %), III (13.4 %), V + III (3.3 %), and V + IV (3.3 %). Activity index is 6.18 ± 4.55 and chronicity index is 1 (0–3). The result of 24-h proteinuria is 2000 mg (667–4770) and baseline creatinine is 0.9 mg/dL (0.7–1.3). Induction therapy includes corticosteroids (100 %), cyclophosphamide (74.1 %), and mycophenolate mofetil (25.9 %). At 12 months, 40.7 % of individuals failed to attain partial or complete remission. Elevated creatinine (p = 0.0001) and 24-h proteinuria greater than 1500 mg (p = 0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline creatinine elevation (OR 3.62, 95 % CI, 1.59–8.23; p = 0.002) and 24-h proteinuria greater than 1500 mg (OR 3.62, 95 % CI, 1.29–10.13; p = 0.014) were independent predictors of failure to achieve partial or complete remission. At 12 months, 40.7 % of patients did not attain partial or complete remission. Baseline elevated creatinine and 24-h proteinuria over 1500 mg were predictors for poor response. Mención de responsabilidad : Luis Fernando Pinto-Peñaranda, Vladimir Duque-Caballero, Javier Darío Márquez-Hernández, Carolina Muñoz-Grajales, Carlos Jaime Velásquez-Franco Referencia : Clin Rheumatol. 2015 May;34(5):897-903. DOI (Digital Object Identifier) : 10.1007/s10067-015-2864-7 PMID : 25592376 En línea : https://link.springer.com/article/10.1007%2Fs10067-015-2864-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000467	AC-2015-020	Archivo digital	Producción Científica	Artículos científicos	Disponible

Clinical and immunological factors associated with lupus nephritis in patients from northwestern Colombia / Luis Fernando Pinto Peñaranda  

Permalink